UCB (OTCMKTS:UCBJF) Shares Gap Up – Should You Buy?

UCB SA (OTCMKTS:UCBJF)’s share price gapped up prior to trading on Friday . The stock had previously closed at $277.4375, but opened at $290.59. UCB shares last traded at $290.59, with a volume of 49 shares.

Analysts Set New Price Targets

Separately, Piper Sandler reiterated a “neutral” rating on shares of UCB in a research report on Wednesday. Six investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

UCB Stock Up 4.7%

The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The company has a 50-day moving average price of $292.32 and a 200 day moving average price of $300.73.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.